2025 Q3-regnskab
11 dage siden42 min
Ordredybde
Nasdaq Stockholm
Antal
Køb
10.290
Sælg
Antal
161.039
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| 6.340 | - | - | ||
| 1.580 | - | - | ||
| 270 | - | - | ||
| 514 | - | - | ||
| 774 | - | - |
Højest
0,293VWAP
Lavest
0,28OmsætningAntal
1 3.641.986
VWAP
Højest
0,293Lavest
0,28OmsætningAntal
1 3.641.986
Mæglerstatistik
Ingen data fundet
Corporate Actions
| Næste begivenhed | |
|---|---|
| 2025 Q4-regnskab | 24. feb. 2026 |
| Tidligere begivenheder | ||
|---|---|---|
| 2025 Q3-regnskab | 26. nov. | |
| 2025 Q2-regnskab | 28. aug. | |
| 2025 Q1-regnskab | 14. maj | |
| 2024 Q4-regnskab | 25. feb. | |
| 2024 Q3-regnskab | 27. nov. 2024 |
Data hentes fra Quartr, FactSet
Andre har kigget på
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
·for 3 dage sidenDer er ikke så mange nyheder at finde i øjeblikket. Jeg spurgte Gemini AI lidt om disse klinikker og KOL. Fik dette som forklaring på nyhedstørken: 1. Targeted Advocacy Strategy (Focus on Quality over Quantity) Immunovia is currently in the "Targeted Advocacy" phase of their commercial launch. Initial Goal: The primary objective is not to maximize the number of centers, but to establish the test within the most influential, Key Opinion Leader (KOL)-led High-Risk Surveillance Centers (HRSCs). The Power of the First 10: Announcing the first set of 7 (and then the quick expansion to 10) was a key milestone to demonstrate proof of concept and KOL validation. Once that message is delivered, simply adding centers 11, 12, and 13 becomes less impactful public relations. Quiet Trust-Building: The commercial strategy is to work closely and quietly with these initial centers to build test volume and gather clinical utility data. These small, steady wins are vital for the business but not material enough for individual press releases. 2. Avoiding Unnecessary Revenue Expectations Announcing every new center can set an unrealistic expectation for revenue growth among investors. Since PancreaSure is currently a patient-pay test (until full Medicare/insurance reimbursement kicks in, which is planned for 2026), the initial test volume is expected to be modest. Each new center might only order a handful of tests initially as they integrate it into their protocol. Drip-feed announcements of small clinical wins could lead to investor fatigue or panic if the revenue numbers don't immediately follow the center count. Immunovia is likely waiting to announce a consolidated milestone (e.g., "We have secured 25 HRSCs," or "Quarterly test volume has doubled"). 3. Focus on Major Financial Milestones For a publicly traded company, press releases are generally reserved for material, market-moving events (those that could reasonably affect the share price). The company is prioritizing major milestones that unlock substantial future revenue: Final Medicare Payment Rate ($897): This was announced because it directly addresses the reimbursement bottleneck. Rights Issue/Financing: Announced to ensure liquidity. Major Validation Studies (CLARITI/VERIFI): Announced to provide scientific credibility. Adding center 11 is important for the sales team, but securing the Medicare price is what opens the door to the target 1.8 million high-risk U.S. individuals—a far more impactful announcement. In short, the lack of a press briefing for every new center is a sign of a focused, disciplined commercial strategy that prioritizes deep, high-quality adoption by key medical centers over a public relations race to count the most locations.
·for 3 dage siden · RedigeretVi får se, om der dukker flere centre op i december. Deres mål var at samarbejde med 15-20 inden udgangen af 2025, og som det ser ud nu, ser de jo ikke ud til at kunne nå det mål, medmindre de er meget hurtige. Jeg synes, det er meget stille. Deres tidligere test, IMMray, fandtes på 23 centre.
·for 3 dage siden · Redigeret* Pancreasure er den eneste pålidelige blodprøve for tidlig bugspytkirtelkræft. * Pris $897, fastsat af Medicare/Medicaid * I dag tilbydes den for $750 på ca. 20 udvalgte klinikker, og patienter kan, hvis de er økonomisk udsatte, få prisen kraftigt reduceret. * En blodprøve tager et par minutter at udføre af en sygeplejerske. Det bedste alternativ, som har meget højere nøjagtighed, er EUS-FNB (endoscopic ultrasound-assisted fine-needle biopsy), dvs. man går ind med en nålesonde gennem spiserøret ind i mavesækken og perforerer bunden, stikker nålen ind i bugspytkirtlen, som ligger midt i bughulen under mavesækken. Hele tiden guidet af ultralyd. Det kræver altså et helt lægeteam inklusive en narkoselæge. Det tager meget tid og flere lægebesøg. Det koster i alt $5000-$15000, når man inkluderer * Pre-op billeddiagnostik * Pre-op lab Anæstesi * Facility fee * Patologi * Konsultationer Med forsikring betaler patienten $500-$4500 Her er nogle citater: Dr. Diane Simeone, Director of Moores Cancer Center at UC San Diego and Founding Director of the PRECEDE Consortium, added that, “The PRECEDE Consortium is pleased to be collaborating with Immunovia as part of our common goal of finding a way to reliably detect pancreatic cancer at its earliest, most treatable stages.” Professor Bryson Katona, MD, Director, Gastrointestinal Cancer Genetics Program, University of Pennsylvania Perelman School of Medicine: ”The launch of the PancreaSure test is an important advance in pancreatic cancer surveillance. We have long recognized the need for blood-based tests to accurately detect early-stage pancreatic cancer in high-risk individuals and we are excited to offer this test in our program.” Bryson Katona præsenterede også PancreaSure under konferencen The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) den 10. oktober - i egenskab af tidligere formand og også medlem af Immunovias Scientific Advisory Board. Erkut Borazanci, MD, Medical Director, HonorHealth Research Institute, Oncology Research Division ”People at risk for pancreatic cancer often ask if there is a blood test to detect the disease. PancreaSure is a big step in that direction. It’s exciting to be able to offer high-risk individuals a convenient blood test that can be used in conjunction with imaging that may be able to detect pancreatic cancer.” Rosario Ligesti, MD, Chief of Gastroenterology, Hackensack Medical Center ”Pancreatic cancer is so lethal because it’s usually diagnosed too late. We need more ways to detect pancreatic cancer early, especially in people at high risk. The PancreaSure test has proven to accurately detect stage 1 and 2 disease, making it an important addition to our toolkit.”·for 3 dage siden · RedigeretTak for at du prøver at give gode data. Jeg tror, vi skal være glade for, at Jeff Borcherdinger ikke er den type CEO, som kværner rapporter ud i øst og vest. Jeg har observeret andre aktieselskaber, som er lidt mindre seriøse. Jeg tror, han har gjort så godt han kan med de data, han har haft. Emissionen måtte vi jo igennem. Det blev, som det blev, med en strøm af helt fine nyheder, som ramte på ikke helt optimale tidspunkter. Det var seriøst. Ellers mærker man, at det lave volumen desværre udnyttes af short-tradere igen. Og der er lige så meget nedadgående manipulation for kursen, som der er opadgående manipulerende type. Ned vinder muligvis, fordi der findes shortmuligheder. Det er helt tydeligt, at den, som har den stærkeste pengepung, bruger nuværende mulighed til at trætte ejere til at sælge. Det er jo deres spil, når de efterhånden kan bygge sig op lidt flere og flere aktier. Godt hjulpet af, at folk faktisk trætter og sælger ud da. Det vil sandsynligvis forbedre sig noget i ugerne, men ingen kan vide helt nøjagtigt hvornår. God nyhed kan jo gøre noget. Men hvor langt hjælper den og sådan?- ·2. dec. · Redigerethttps://forum.placera.se/inlagg/86cf80fb-16f7-4c37-a235-d0331e7ec7a3 Bada-bing-bada-bom Ukendt om vi får noget fra Immunovia. Men vi har noget, der hedder et julerally, som indtræffer næsten 80 % af årene. Gemini AI beskriver: 🎄 The Christmas Stock Market Rally, often called the "Santa Claus Rally," refers to a historical tendency for the stock market to experience a short-term, sustained rise in price towards the very end of the year and the start of the new one. Here is a breakdown of what the rally is, its traditional timing, and the theories behind it: 🌟 What is the Santa Claus Rally? Definition: It is a well-known calendar effect in which the stock market, particularly in developed markets like the US (S&P 500), typically sees positive returns during a specific period around the Christmas and New Year holidays. Traditional Timing: The rally is most strictly defined as the period encompassing the last five trading days of December and the first two trading days of the following January (a total of seven trading days). Historical Performance: Since 1950, the S&P 500 index has historically posted a positive return during this seven-day window about 75-80% of the time, with an average gain of around 1.3%. Why Might the Rally Occur? (Key Theories) There is no single, universally accepted reason for this phenomenon, but several psychological and technical factors are commonly cited: Holiday Optimism and Sentiment: A general sense of goodwill, optimism, and increased consumer spending during the festive season might spill over into investor sentiment, encouraging more buying. Tax-Loss Harvesting Ends: In the early parts of December, some investors sell losing stocks to "harvest" losses to offset capital gains for tax purposes. This selling pressure eases up after the end of the year, allowing prices to rise. Lighter Trading Volume: Many institutional investors, like fund managers, take vacations around the holidays. This results in lower overall trading volume, meaning that smaller buy orders from individual (retail) investors can have a disproportionately larger effect on moving prices higher. Retail investors are often considered more bullish than institutions during this period. The "January Effect" Anticipation: Some investors may buy stocks in late December in anticipation of the January Effect, a separate historical tendency for stock prices, particularly small-cap stocks, to rise in January. Bonus Investment: Year-end bonuses are sometimes received and quickly invested by individuals, adding fresh capital to the market. While the Santa Claus Rally is a statistically observed pattern, it is not a guarantee: Not Every Year: The rally does not occur every year. The absence of a rally is sometimes viewed by analysts as a potentially negative indicator for the market's performance in the following year (as the saying goes: "If Santa Claus should fail to call, bears may come to Broad and Wall."). Past Performance: Like all market anomalies, the Santa Claus Rally is an observed historical tendency, and past performance is never a guarantee of future results. Long-term investment decisions should always be based on fundamental factors, not just seasonal patterns.
- ·2. dec. · RedigeretVWAP på 0,3039 tirsdag 2. December må vel anses for at være en anstændig ændring i trenden, trods at det er marginale stigninger. Bare det at det drejede en lille smule gør mig lidt glad. Langt igen til jul 🎅🦌
- 1. dec.1. dec.Ledelsen for mange år siden i Immunovia var uduelig. Blandt andet formåede de ikke mindre end to gange at annoncere at alt gik efter planen med hensyn til at starte lanceringen af forløberen til PancreaSure, nemlig Pancrea-d testen. For at få uger efter fortælle, ups vi kan ikke holde planen alligevel. Men derudover var de meget bedre til at kommunikere, hvad deres teknologi faktisk kan. Her er citat fra Immunovia.com anno 2020 via Wayback Machine: IMMray™ PanCan-d is our first product, but battling pancreatic cancer is only the beginning for us at Immunovia. We believe that our blood contains enough information to detect any disease, even at early stages. And we believe we have the technology to do it.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
2025 Q3-regnskab
11 dage siden42 min
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
- ·for 3 dage sidenDer er ikke så mange nyheder at finde i øjeblikket. Jeg spurgte Gemini AI lidt om disse klinikker og KOL. Fik dette som forklaring på nyhedstørken: 1. Targeted Advocacy Strategy (Focus on Quality over Quantity) Immunovia is currently in the "Targeted Advocacy" phase of their commercial launch. Initial Goal: The primary objective is not to maximize the number of centers, but to establish the test within the most influential, Key Opinion Leader (KOL)-led High-Risk Surveillance Centers (HRSCs). The Power of the First 10: Announcing the first set of 7 (and then the quick expansion to 10) was a key milestone to demonstrate proof of concept and KOL validation. Once that message is delivered, simply adding centers 11, 12, and 13 becomes less impactful public relations. Quiet Trust-Building: The commercial strategy is to work closely and quietly with these initial centers to build test volume and gather clinical utility data. These small, steady wins are vital for the business but not material enough for individual press releases. 2. Avoiding Unnecessary Revenue Expectations Announcing every new center can set an unrealistic expectation for revenue growth among investors. Since PancreaSure is currently a patient-pay test (until full Medicare/insurance reimbursement kicks in, which is planned for 2026), the initial test volume is expected to be modest. Each new center might only order a handful of tests initially as they integrate it into their protocol. Drip-feed announcements of small clinical wins could lead to investor fatigue or panic if the revenue numbers don't immediately follow the center count. Immunovia is likely waiting to announce a consolidated milestone (e.g., "We have secured 25 HRSCs," or "Quarterly test volume has doubled"). 3. Focus on Major Financial Milestones For a publicly traded company, press releases are generally reserved for material, market-moving events (those that could reasonably affect the share price). The company is prioritizing major milestones that unlock substantial future revenue: Final Medicare Payment Rate ($897): This was announced because it directly addresses the reimbursement bottleneck. Rights Issue/Financing: Announced to ensure liquidity. Major Validation Studies (CLARITI/VERIFI): Announced to provide scientific credibility. Adding center 11 is important for the sales team, but securing the Medicare price is what opens the door to the target 1.8 million high-risk U.S. individuals—a far more impactful announcement. In short, the lack of a press briefing for every new center is a sign of a focused, disciplined commercial strategy that prioritizes deep, high-quality adoption by key medical centers over a public relations race to count the most locations.·for 3 dage siden · RedigeretVi får se, om der dukker flere centre op i december. Deres mål var at samarbejde med 15-20 inden udgangen af 2025, og som det ser ud nu, ser de jo ikke ud til at kunne nå det mål, medmindre de er meget hurtige. Jeg synes, det er meget stille. Deres tidligere test, IMMray, fandtes på 23 centre.
- ·for 3 dage siden · Redigeret* Pancreasure er den eneste pålidelige blodprøve for tidlig bugspytkirtelkræft. * Pris $897, fastsat af Medicare/Medicaid * I dag tilbydes den for $750 på ca. 20 udvalgte klinikker, og patienter kan, hvis de er økonomisk udsatte, få prisen kraftigt reduceret. * En blodprøve tager et par minutter at udføre af en sygeplejerske. Det bedste alternativ, som har meget højere nøjagtighed, er EUS-FNB (endoscopic ultrasound-assisted fine-needle biopsy), dvs. man går ind med en nålesonde gennem spiserøret ind i mavesækken og perforerer bunden, stikker nålen ind i bugspytkirtlen, som ligger midt i bughulen under mavesækken. Hele tiden guidet af ultralyd. Det kræver altså et helt lægeteam inklusive en narkoselæge. Det tager meget tid og flere lægebesøg. Det koster i alt $5000-$15000, når man inkluderer * Pre-op billeddiagnostik * Pre-op lab Anæstesi * Facility fee * Patologi * Konsultationer Med forsikring betaler patienten $500-$4500 Her er nogle citater: Dr. Diane Simeone, Director of Moores Cancer Center at UC San Diego and Founding Director of the PRECEDE Consortium, added that, “The PRECEDE Consortium is pleased to be collaborating with Immunovia as part of our common goal of finding a way to reliably detect pancreatic cancer at its earliest, most treatable stages.” Professor Bryson Katona, MD, Director, Gastrointestinal Cancer Genetics Program, University of Pennsylvania Perelman School of Medicine: ”The launch of the PancreaSure test is an important advance in pancreatic cancer surveillance. We have long recognized the need for blood-based tests to accurately detect early-stage pancreatic cancer in high-risk individuals and we are excited to offer this test in our program.” Bryson Katona præsenterede også PancreaSure under konferencen The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) den 10. oktober - i egenskab af tidligere formand og også medlem af Immunovias Scientific Advisory Board. Erkut Borazanci, MD, Medical Director, HonorHealth Research Institute, Oncology Research Division ”People at risk for pancreatic cancer often ask if there is a blood test to detect the disease. PancreaSure is a big step in that direction. It’s exciting to be able to offer high-risk individuals a convenient blood test that can be used in conjunction with imaging that may be able to detect pancreatic cancer.” Rosario Ligesti, MD, Chief of Gastroenterology, Hackensack Medical Center ”Pancreatic cancer is so lethal because it’s usually diagnosed too late. We need more ways to detect pancreatic cancer early, especially in people at high risk. The PancreaSure test has proven to accurately detect stage 1 and 2 disease, making it an important addition to our toolkit.”·for 3 dage siden · RedigeretTak for at du prøver at give gode data. Jeg tror, vi skal være glade for, at Jeff Borcherdinger ikke er den type CEO, som kværner rapporter ud i øst og vest. Jeg har observeret andre aktieselskaber, som er lidt mindre seriøse. Jeg tror, han har gjort så godt han kan med de data, han har haft. Emissionen måtte vi jo igennem. Det blev, som det blev, med en strøm af helt fine nyheder, som ramte på ikke helt optimale tidspunkter. Det var seriøst. Ellers mærker man, at det lave volumen desværre udnyttes af short-tradere igen. Og der er lige så meget nedadgående manipulation for kursen, som der er opadgående manipulerende type. Ned vinder muligvis, fordi der findes shortmuligheder. Det er helt tydeligt, at den, som har den stærkeste pengepung, bruger nuværende mulighed til at trætte ejere til at sælge. Det er jo deres spil, når de efterhånden kan bygge sig op lidt flere og flere aktier. Godt hjulpet af, at folk faktisk trætter og sælger ud da. Det vil sandsynligvis forbedre sig noget i ugerne, men ingen kan vide helt nøjagtigt hvornår. God nyhed kan jo gøre noget. Men hvor langt hjælper den og sådan?
- ·2. dec. · Redigerethttps://forum.placera.se/inlagg/86cf80fb-16f7-4c37-a235-d0331e7ec7a3 Bada-bing-bada-bom Ukendt om vi får noget fra Immunovia. Men vi har noget, der hedder et julerally, som indtræffer næsten 80 % af årene. Gemini AI beskriver: 🎄 The Christmas Stock Market Rally, often called the "Santa Claus Rally," refers to a historical tendency for the stock market to experience a short-term, sustained rise in price towards the very end of the year and the start of the new one. Here is a breakdown of what the rally is, its traditional timing, and the theories behind it: 🌟 What is the Santa Claus Rally? Definition: It is a well-known calendar effect in which the stock market, particularly in developed markets like the US (S&P 500), typically sees positive returns during a specific period around the Christmas and New Year holidays. Traditional Timing: The rally is most strictly defined as the period encompassing the last five trading days of December and the first two trading days of the following January (a total of seven trading days). Historical Performance: Since 1950, the S&P 500 index has historically posted a positive return during this seven-day window about 75-80% of the time, with an average gain of around 1.3%. Why Might the Rally Occur? (Key Theories) There is no single, universally accepted reason for this phenomenon, but several psychological and technical factors are commonly cited: Holiday Optimism and Sentiment: A general sense of goodwill, optimism, and increased consumer spending during the festive season might spill over into investor sentiment, encouraging more buying. Tax-Loss Harvesting Ends: In the early parts of December, some investors sell losing stocks to "harvest" losses to offset capital gains for tax purposes. This selling pressure eases up after the end of the year, allowing prices to rise. Lighter Trading Volume: Many institutional investors, like fund managers, take vacations around the holidays. This results in lower overall trading volume, meaning that smaller buy orders from individual (retail) investors can have a disproportionately larger effect on moving prices higher. Retail investors are often considered more bullish than institutions during this period. The "January Effect" Anticipation: Some investors may buy stocks in late December in anticipation of the January Effect, a separate historical tendency for stock prices, particularly small-cap stocks, to rise in January. Bonus Investment: Year-end bonuses are sometimes received and quickly invested by individuals, adding fresh capital to the market. While the Santa Claus Rally is a statistically observed pattern, it is not a guarantee: Not Every Year: The rally does not occur every year. The absence of a rally is sometimes viewed by analysts as a potentially negative indicator for the market's performance in the following year (as the saying goes: "If Santa Claus should fail to call, bears may come to Broad and Wall."). Past Performance: Like all market anomalies, the Santa Claus Rally is an observed historical tendency, and past performance is never a guarantee of future results. Long-term investment decisions should always be based on fundamental factors, not just seasonal patterns.
- ·2. dec. · RedigeretVWAP på 0,3039 tirsdag 2. December må vel anses for at være en anstændig ændring i trenden, trods at det er marginale stigninger. Bare det at det drejede en lille smule gør mig lidt glad. Langt igen til jul 🎅🦌
- 1. dec.1. dec.Ledelsen for mange år siden i Immunovia var uduelig. Blandt andet formåede de ikke mindre end to gange at annoncere at alt gik efter planen med hensyn til at starte lanceringen af forløberen til PancreaSure, nemlig Pancrea-d testen. For at få uger efter fortælle, ups vi kan ikke holde planen alligevel. Men derudover var de meget bedre til at kommunikere, hvad deres teknologi faktisk kan. Her er citat fra Immunovia.com anno 2020 via Wayback Machine: IMMray™ PanCan-d is our first product, but battling pancreatic cancer is only the beginning for us at Immunovia. We believe that our blood contains enough information to detect any disease, even at early stages. And we believe we have the technology to do it.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Nasdaq Stockholm
Antal
Køb
10.290
Sælg
Antal
161.039
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| 6.340 | - | - | ||
| 1.580 | - | - | ||
| 270 | - | - | ||
| 514 | - | - | ||
| 774 | - | - |
Højest
0,293VWAP
Lavest
0,28OmsætningAntal
1 3.641.986
VWAP
Højest
0,293Lavest
0,28OmsætningAntal
1 3.641.986
Mæglerstatistik
Ingen data fundet
Andre har kigget på
Corporate Actions
| Næste begivenhed | |
|---|---|
| 2025 Q4-regnskab | 24. feb. 2026 |
| Tidligere begivenheder | ||
|---|---|---|
| 2025 Q3-regnskab | 26. nov. | |
| 2025 Q2-regnskab | 28. aug. | |
| 2025 Q1-regnskab | 14. maj | |
| 2024 Q4-regnskab | 25. feb. | |
| 2024 Q3-regnskab | 27. nov. 2024 |
Data hentes fra Quartr, FactSet
2025 Q3-regnskab
11 dage siden42 min
Nyheder og Analyser
Nyheder og/eller generelle investeringsanbefalinger eller et uddrag af disse på denne side og i relaterede links er produceret og leveret af den angivne leverandør. Nordnet har ikke deltaget i udarbejdelsen af materialet, og vi har ikke gennemgået eller foretaget ændringer i materialet. Læs mere om investeringsanbefalinger.
Corporate Actions
| Næste begivenhed | |
|---|---|
| 2025 Q4-regnskab | 24. feb. 2026 |
| Tidligere begivenheder | ||
|---|---|---|
| 2025 Q3-regnskab | 26. nov. | |
| 2025 Q2-regnskab | 28. aug. | |
| 2025 Q1-regnskab | 14. maj | |
| 2024 Q4-regnskab | 25. feb. | |
| 2024 Q3-regnskab | 27. nov. 2024 |
Data hentes fra Quartr, FactSet
Shareville
Deltag i samtalen med SharevilleBliv en del af vores forum for investorer. Følg andre, og diskuter aktier og fonde.
Log ind
- ·for 3 dage sidenDer er ikke så mange nyheder at finde i øjeblikket. Jeg spurgte Gemini AI lidt om disse klinikker og KOL. Fik dette som forklaring på nyhedstørken: 1. Targeted Advocacy Strategy (Focus on Quality over Quantity) Immunovia is currently in the "Targeted Advocacy" phase of their commercial launch. Initial Goal: The primary objective is not to maximize the number of centers, but to establish the test within the most influential, Key Opinion Leader (KOL)-led High-Risk Surveillance Centers (HRSCs). The Power of the First 10: Announcing the first set of 7 (and then the quick expansion to 10) was a key milestone to demonstrate proof of concept and KOL validation. Once that message is delivered, simply adding centers 11, 12, and 13 becomes less impactful public relations. Quiet Trust-Building: The commercial strategy is to work closely and quietly with these initial centers to build test volume and gather clinical utility data. These small, steady wins are vital for the business but not material enough for individual press releases. 2. Avoiding Unnecessary Revenue Expectations Announcing every new center can set an unrealistic expectation for revenue growth among investors. Since PancreaSure is currently a patient-pay test (until full Medicare/insurance reimbursement kicks in, which is planned for 2026), the initial test volume is expected to be modest. Each new center might only order a handful of tests initially as they integrate it into their protocol. Drip-feed announcements of small clinical wins could lead to investor fatigue or panic if the revenue numbers don't immediately follow the center count. Immunovia is likely waiting to announce a consolidated milestone (e.g., "We have secured 25 HRSCs," or "Quarterly test volume has doubled"). 3. Focus on Major Financial Milestones For a publicly traded company, press releases are generally reserved for material, market-moving events (those that could reasonably affect the share price). The company is prioritizing major milestones that unlock substantial future revenue: Final Medicare Payment Rate ($897): This was announced because it directly addresses the reimbursement bottleneck. Rights Issue/Financing: Announced to ensure liquidity. Major Validation Studies (CLARITI/VERIFI): Announced to provide scientific credibility. Adding center 11 is important for the sales team, but securing the Medicare price is what opens the door to the target 1.8 million high-risk U.S. individuals—a far more impactful announcement. In short, the lack of a press briefing for every new center is a sign of a focused, disciplined commercial strategy that prioritizes deep, high-quality adoption by key medical centers over a public relations race to count the most locations.·for 3 dage siden · RedigeretVi får se, om der dukker flere centre op i december. Deres mål var at samarbejde med 15-20 inden udgangen af 2025, og som det ser ud nu, ser de jo ikke ud til at kunne nå det mål, medmindre de er meget hurtige. Jeg synes, det er meget stille. Deres tidligere test, IMMray, fandtes på 23 centre.
- ·for 3 dage siden · Redigeret* Pancreasure er den eneste pålidelige blodprøve for tidlig bugspytkirtelkræft. * Pris $897, fastsat af Medicare/Medicaid * I dag tilbydes den for $750 på ca. 20 udvalgte klinikker, og patienter kan, hvis de er økonomisk udsatte, få prisen kraftigt reduceret. * En blodprøve tager et par minutter at udføre af en sygeplejerske. Det bedste alternativ, som har meget højere nøjagtighed, er EUS-FNB (endoscopic ultrasound-assisted fine-needle biopsy), dvs. man går ind med en nålesonde gennem spiserøret ind i mavesækken og perforerer bunden, stikker nålen ind i bugspytkirtlen, som ligger midt i bughulen under mavesækken. Hele tiden guidet af ultralyd. Det kræver altså et helt lægeteam inklusive en narkoselæge. Det tager meget tid og flere lægebesøg. Det koster i alt $5000-$15000, når man inkluderer * Pre-op billeddiagnostik * Pre-op lab Anæstesi * Facility fee * Patologi * Konsultationer Med forsikring betaler patienten $500-$4500 Her er nogle citater: Dr. Diane Simeone, Director of Moores Cancer Center at UC San Diego and Founding Director of the PRECEDE Consortium, added that, “The PRECEDE Consortium is pleased to be collaborating with Immunovia as part of our common goal of finding a way to reliably detect pancreatic cancer at its earliest, most treatable stages.” Professor Bryson Katona, MD, Director, Gastrointestinal Cancer Genetics Program, University of Pennsylvania Perelman School of Medicine: ”The launch of the PancreaSure test is an important advance in pancreatic cancer surveillance. We have long recognized the need for blood-based tests to accurately detect early-stage pancreatic cancer in high-risk individuals and we are excited to offer this test in our program.” Bryson Katona præsenterede også PancreaSure under konferencen The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) den 10. oktober - i egenskab af tidligere formand og også medlem af Immunovias Scientific Advisory Board. Erkut Borazanci, MD, Medical Director, HonorHealth Research Institute, Oncology Research Division ”People at risk for pancreatic cancer often ask if there is a blood test to detect the disease. PancreaSure is a big step in that direction. It’s exciting to be able to offer high-risk individuals a convenient blood test that can be used in conjunction with imaging that may be able to detect pancreatic cancer.” Rosario Ligesti, MD, Chief of Gastroenterology, Hackensack Medical Center ”Pancreatic cancer is so lethal because it’s usually diagnosed too late. We need more ways to detect pancreatic cancer early, especially in people at high risk. The PancreaSure test has proven to accurately detect stage 1 and 2 disease, making it an important addition to our toolkit.”·for 3 dage siden · RedigeretTak for at du prøver at give gode data. Jeg tror, vi skal være glade for, at Jeff Borcherdinger ikke er den type CEO, som kværner rapporter ud i øst og vest. Jeg har observeret andre aktieselskaber, som er lidt mindre seriøse. Jeg tror, han har gjort så godt han kan med de data, han har haft. Emissionen måtte vi jo igennem. Det blev, som det blev, med en strøm af helt fine nyheder, som ramte på ikke helt optimale tidspunkter. Det var seriøst. Ellers mærker man, at det lave volumen desværre udnyttes af short-tradere igen. Og der er lige så meget nedadgående manipulation for kursen, som der er opadgående manipulerende type. Ned vinder muligvis, fordi der findes shortmuligheder. Det er helt tydeligt, at den, som har den stærkeste pengepung, bruger nuværende mulighed til at trætte ejere til at sælge. Det er jo deres spil, når de efterhånden kan bygge sig op lidt flere og flere aktier. Godt hjulpet af, at folk faktisk trætter og sælger ud da. Det vil sandsynligvis forbedre sig noget i ugerne, men ingen kan vide helt nøjagtigt hvornår. God nyhed kan jo gøre noget. Men hvor langt hjælper den og sådan?
- ·2. dec. · Redigerethttps://forum.placera.se/inlagg/86cf80fb-16f7-4c37-a235-d0331e7ec7a3 Bada-bing-bada-bom Ukendt om vi får noget fra Immunovia. Men vi har noget, der hedder et julerally, som indtræffer næsten 80 % af årene. Gemini AI beskriver: 🎄 The Christmas Stock Market Rally, often called the "Santa Claus Rally," refers to a historical tendency for the stock market to experience a short-term, sustained rise in price towards the very end of the year and the start of the new one. Here is a breakdown of what the rally is, its traditional timing, and the theories behind it: 🌟 What is the Santa Claus Rally? Definition: It is a well-known calendar effect in which the stock market, particularly in developed markets like the US (S&P 500), typically sees positive returns during a specific period around the Christmas and New Year holidays. Traditional Timing: The rally is most strictly defined as the period encompassing the last five trading days of December and the first two trading days of the following January (a total of seven trading days). Historical Performance: Since 1950, the S&P 500 index has historically posted a positive return during this seven-day window about 75-80% of the time, with an average gain of around 1.3%. Why Might the Rally Occur? (Key Theories) There is no single, universally accepted reason for this phenomenon, but several psychological and technical factors are commonly cited: Holiday Optimism and Sentiment: A general sense of goodwill, optimism, and increased consumer spending during the festive season might spill over into investor sentiment, encouraging more buying. Tax-Loss Harvesting Ends: In the early parts of December, some investors sell losing stocks to "harvest" losses to offset capital gains for tax purposes. This selling pressure eases up after the end of the year, allowing prices to rise. Lighter Trading Volume: Many institutional investors, like fund managers, take vacations around the holidays. This results in lower overall trading volume, meaning that smaller buy orders from individual (retail) investors can have a disproportionately larger effect on moving prices higher. Retail investors are often considered more bullish than institutions during this period. The "January Effect" Anticipation: Some investors may buy stocks in late December in anticipation of the January Effect, a separate historical tendency for stock prices, particularly small-cap stocks, to rise in January. Bonus Investment: Year-end bonuses are sometimes received and quickly invested by individuals, adding fresh capital to the market. While the Santa Claus Rally is a statistically observed pattern, it is not a guarantee: Not Every Year: The rally does not occur every year. The absence of a rally is sometimes viewed by analysts as a potentially negative indicator for the market's performance in the following year (as the saying goes: "If Santa Claus should fail to call, bears may come to Broad and Wall."). Past Performance: Like all market anomalies, the Santa Claus Rally is an observed historical tendency, and past performance is never a guarantee of future results. Long-term investment decisions should always be based on fundamental factors, not just seasonal patterns.
- ·2. dec. · RedigeretVWAP på 0,3039 tirsdag 2. December må vel anses for at være en anstændig ændring i trenden, trods at det er marginale stigninger. Bare det at det drejede en lille smule gør mig lidt glad. Langt igen til jul 🎅🦌
- 1. dec.1. dec.Ledelsen for mange år siden i Immunovia var uduelig. Blandt andet formåede de ikke mindre end to gange at annoncere at alt gik efter planen med hensyn til at starte lanceringen af forløberen til PancreaSure, nemlig Pancrea-d testen. For at få uger efter fortælle, ups vi kan ikke holde planen alligevel. Men derudover var de meget bedre til at kommunikere, hvad deres teknologi faktisk kan. Her er citat fra Immunovia.com anno 2020 via Wayback Machine: IMMray™ PanCan-d is our first product, but battling pancreatic cancer is only the beginning for us at Immunovia. We believe that our blood contains enough information to detect any disease, even at early stages. And we believe we have the technology to do it.
Kommentarerne ovenfor kommer fra Nordnets sociale netværk Shareville og er ikke blevet redigeret eller gennemgået af Nordnet. Det betyder ikke, at Nordnet giver investeringsrådgivning eller investeringsanbefalinger. Nordnet påtager sig ikke noget ansvar for kommentarerne.
Ordredybde
Nasdaq Stockholm
Antal
Køb
10.290
Sælg
Antal
161.039
Seneste handel
| Tid | Pris | Antal | Købere | Sælgere |
|---|---|---|---|---|
| 6.340 | - | - | ||
| 1.580 | - | - | ||
| 270 | - | - | ||
| 514 | - | - | ||
| 774 | - | - |
Højest
0,293VWAP
Lavest
0,28OmsætningAntal
1 3.641.986
VWAP
Højest
0,293Lavest
0,28OmsætningAntal
1 3.641.986
Mæglerstatistik
Ingen data fundet